Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 22, 2017, details the results of Ultragenyx Pharmaceutical Inc.'s Annual Meeting of Stockholders held on that date. The company is incorporated in Delaware and headquartered in Novato, California.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
As of the record date of April 24, 2017, 42,282,287 shares were outstanding. A total of 40,260,307 shares were represented at the meeting. The following proposals were voted upon:
- Proposal 1: Election of Class I Directors
- Emil D. Kakkis, M.D.: Elected with 35,213,316 votes for, 93,310 withheld, and 4,953,681 broker non-votes.
- Daniel G. Welch: Elected with 34,427,957 votes for, 878,669 withheld, and 4,953,681 broker non-votes.
- Proposal 2: Ratification of Independent Registered Accounting Firm
- Ernst & Young LLP was ratified for the fiscal year ending December 31, 2017.
- Votes: 40,223,813 for, 18,716 against, 17,778 abstentions.
- Proposal 3: Advisory Vote on Executive Compensation
- Stockholders voted in favor of the resolution approving executive compensation.
- Votes: 29,616,142 for, 5,665,727 against, 24,757 abstentions, and 4,953,681 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The report is limited to the submission of matters to a vote of security holders.
Key Facts for Investor Verification
- Confirmation that Emil D. Kakkis, M.D., and Daniel G. Welch were elected to the Board of Directors for terms ending in 2020.
- Verification that Ernst & Young LLP remains the independent auditor for the 2017 fiscal year.
- Assessment of the advisory vote on executive compensation, noting approximately 16% of votes cast were against the proposal.
- Review of the high number of broker non-votes (4,953,681) on director elections and executive compensation.